Entera Bio (NASDAQ:ENTX) Trading Up 5.1% – Should You Buy?

Shares of Entera Bio Ltd. (NASDAQ:ENTX) were up 5.1% on Thursday . The company traded as high as $3.24 and last traded at $3.27. Approximately 89,894 shares changed hands during trading, a decline of 92% from the average session volume of 1,130,988 shares. The stock had previously closed at $3.11.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ENTX shares. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Entera Bio Trading Up 0.3%

The firm has a fifty day simple moving average of $2.20 and a 200-day simple moving average of $1.59. The stock has a market cap of $559.24 million, a price-to-earnings ratio of -9.23 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, equities analysts predict that Entera Bio Ltd. will post -0.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

Several institutional investors have recently modified their holdings of ENTX. Citadel Advisors LLC raised its stake in shares of Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after buying an additional 28,322 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares during the period. Renaissance Technologies LLC boosted its position in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the period. Finally, Schonfeld Strategic Advisors LLC increased its holdings in Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after purchasing an additional 29,629 shares during the last quarter. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.